TY - JOUR
T1 - CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation
AU - Stasia, Alessandra
AU - Ghiso, Anna
AU - Galaverna, Federica
AU - Raiola, Anna Maria
AU - Gualandi, Francesca
AU - Luchetti, Silvia
AU - Pozzi, Sarah
AU - Varaldo, Riccardo
AU - Lamparelli, Teresa
AU - Bregante, Stefania
AU - Van Lint, Maria Teresa
AU - di Grazia, Carmen
AU - Bacigalupo, Andrea
PY - 2014
Y1 - 2014
N2 - Poor graft function (PGF) is characterized by pancytopenia and a hypoplastic marrow, with complete donor chimerism, usually without severe graft-versus-host disease (GVHD). We report 41 patients with PGF, treated with granulocyte colony-stimulating factor-mobilized CD34 selected cells, at a median interval from transplant of 140days, without conditioning and without GVHD prophylaxis. Donors were HLA matched siblings (n=12), unrelated donors (n=18), or mismatched family members (n=11). The median number of infused CD34+ cells was 3.4×106/kg. The rate of trilineage recovery was 75%: 83% for HLA matched siblings and 72% for unrelated and mismatched family members (P=3). The cumulative incidence of acute grade II GVHD was 15%, and no patient developed de novo chronic GVHD. The actuarial 3-year survival is 63%: 76% and 25% for patients with or without trilineage recovery. These data confirm the role of CD34+ selected cells from the same donor in the treatment of PGF and warrant the request for a second donation also when the donor is unrelated.
AB - Poor graft function (PGF) is characterized by pancytopenia and a hypoplastic marrow, with complete donor chimerism, usually without severe graft-versus-host disease (GVHD). We report 41 patients with PGF, treated with granulocyte colony-stimulating factor-mobilized CD34 selected cells, at a median interval from transplant of 140days, without conditioning and without GVHD prophylaxis. Donors were HLA matched siblings (n=12), unrelated donors (n=18), or mismatched family members (n=11). The median number of infused CD34+ cells was 3.4×106/kg. The rate of trilineage recovery was 75%: 83% for HLA matched siblings and 72% for unrelated and mismatched family members (P=3). The cumulative incidence of acute grade II GVHD was 15%, and no patient developed de novo chronic GVHD. The actuarial 3-year survival is 63%: 76% and 25% for patients with or without trilineage recovery. These data confirm the role of CD34+ selected cells from the same donor in the treatment of PGF and warrant the request for a second donation also when the donor is unrelated.
KW - Allogeneic stem cell transplants
KW - CD34
KW - GVHD
KW - Poor graft function
KW - Rejection
UR - http://www.scopus.com/inward/record.url?scp=84905563115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905563115&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.05.016
DO - 10.1016/j.bbmt.2014.05.016
M3 - Article
C2 - 24862637
AN - SCOPUS:84905563115
VL - 20
SP - 1440
EP - 1443
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 9
ER -